Page 3 - Kidney Int Rep News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

/PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd.

United kingdomUnited statesKaren molyneuxRichard lafayetteRichard philipsonEuropean renal associationExchange commissionEuropean commissionUniversity of leicesterCalliditas therapeuticsNasdaq stockholmNeflgard phaseNefigard phasePresentation detailsStanford healthcareKidney inflammation

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 (2)

STOCKHOLM, May 5, 2023 /PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX).

United kingdomUnited statesRichard philipsonKaren molyneuxRichard lafayetteEuropean commissionUniversity of leicesterExchange commissionEuropean renal associationNasdaq stockholmNeflgard phaseNefigard phasePresentation detailsStanford healthcareKidney inflammationIga nephropathy

Calliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with IgA Nephropathy in the United States

Calliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with IgA Nephropathy in the United States
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLifesci communicationtelMaya romanchukAndrew udellMarie galayOutcomes researchExchange commissionNasdaq stockholmPrimary iga nephropathyNorth americaFull prescribingIga nephropathyPrimary immunoglobulinCalliditascalliditas therapeuticsNasdaq global select marketLooking statementsthis

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

/PRNewswire/ Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global,.

United statesUnited kingdomMarie galayVilla bacaExchange commissionKidney internationalEuropean commissionNefigard toplineFull prescribing informationPrimary immunoglobulinNasdaq stockholmAmerican depositary sharesNasdaq global select marketPrivate securities litigation reform actCalliditas therapeuticsLife expectancy

Calliditas Therapeutics: Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO (budesonide) in IgA Nephropathy

STOCKHOLM, Oct. 19, 2022 /PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the successful

Marie galayVilla bacaExchange commissionKidney international press releaseKidney internationalLifesci communicationsNasdaq stockholmNefigard partNefigard phaseChief executive officerFull prescribing informationPrimary immunoglobulinNasdaq global select marketPrivate securities litigation reform actInvestor relations managerCalliditas media contact